- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.02. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago | 1 | GlobeNewswire (USA) | ||
| 23.02. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution | 1 | GlobeNewswire (USA) | ||
| 20.02. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.02. | JUPITER NEUROSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 28.01. | Jupiter Neurosciences launches support initiative for GLP-1 users | 3 | Investing.com | ||
| 28.01. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users | 1.259 | GlobeNewswire (Europe) | Nugevia supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:... ► Artikel lesen | |
| JUPITER NEUROSCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.01. | DealFlow Events: Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference | 261 | ACCESS Newswire | JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform for neuroinflammation... ► Artikel lesen | |
| 22.12.25 | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.12.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum | 3 | GlobeNewswire (USA) | ||
| 02.12.25 | Noble Financial Group, Inc.: Jupiter Neurosciences to Participate in NobleCon21 | 407 | Newsfile | Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based therapeutic... ► Artikel lesen | |
| 26.11.25 | JUPITER NEUROSCIENCES, INC. - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 14.11.25 | JUPITER NEUROSCIENCES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | FDA clears Jupiter Neurosciences' IND for Parkinson's drug trial | 1 | Investing.com | ||
| 27.10.25 | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.10.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing | 1 | GlobeNewswire (USA) | ||
| 23.07.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Highlights Critical Advancement of JOTROL Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science | 274 | GlobeNewswire (Europe) | Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company")... ► Artikel lesen | |
| 10.07.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement | 295 | GlobeNewswire (Europe) | Nasdaq compliance follows positive upward trend in Company's Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company")... ► Artikel lesen | |
| 12.06.25 | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | 1.089 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| 09.06.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Launches Nugevia: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science | 1.558 | GlobeNewswire (Europe) | First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TONIX PHARMACEUTICALS | 13,200 | +1,54 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 | ||
| BRIGHT MINDS BIOSCIENCES | 74,10 | +2,96 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| BAYER | 37,765 | -0,96 % | EQS-News: Formycon AG: Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit Regeneron und Bayer | EQS-News: Formycon AG
/ Schlagwort(e): Sonstiges
Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit... ► Artikel lesen | |
| NOVO NORDISK | 30,695 | -3,11 % | Milliardenmarkt vor Umbruch: Angriff auf Eli Lilly und Novo Nordisk: Roche wittert Milliardenchance | © Foto: Udo Herrmann - picture alliance / CHROMORANGERoche will im boomenden Markt für Abnehm-Medikamente wieder angreifen. Der Konzern setzt auf neue Strategien und Milliarden-Deals im Wettbewerb.Der... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 23,840 | 0,00 % | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS... ► Artikel lesen | |
| DERMAPHARM | 42,650 | 0,00 % | EQS-AFR: Dermapharm Holding SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Dermapharm Holding SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Dermapharm Holding SE: Vorabbekanntmachung... ► Artikel lesen | |
| MERCK KGAA | 105,50 | -0,61 % | EQS-DD: Merck KGaA: Belén Garijo Lopez, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
25.03.2026 / 10:59... ► Artikel lesen | |
| HARROW | 36,340 | 0,00 % | Harrow prices $50 million debt offering at 8.625% due 2030 | ||
| NRX PHARMACEUTICALS | 2,100 | +0,96 % | NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101 | ||
| PFIZER | 23,575 | -0,25 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 13,115 | 0,00 % | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,215 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer | Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary... ► Artikel lesen | |
| SANOFI | 80,35 | +1,22 % | BERENBERG stuft SANOFI auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Sanofi mit einem Kursziel von 105 Euro auf "Buy" belassen. Die Zurückhaltung der Anleger vor der Strategievorstellung des neuen Chefs bremse... ► Artikel lesen | |
| LB PHARMACEUTICALS | 24,100 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia | LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at... ► Artikel lesen | |
| ASPIRE BIOPHARMA | 1,110 | 0,00 % | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion | Agreement Set to Expand BUZZ BOMB Distribution Across Natural, Specialty, and Mass Merchandiser Channels ESTERO, FL / ACCESS Newswire / March 19, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)... ► Artikel lesen |
Das Unternehmen JUPITER NEUROSCIENCES INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,385 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JUPITER NEUROSCIENCES INC finden Sie auf Wallstreet Online.